Arcturus Therapeutics Holdings Inc.

ARCTNASDAQHealthcare● Active

$7.12

$-0.18(-2.47%)

Market Cap$202372251

P/E Ratio—

52W High$24.17

52W Low$5.85

Avg Volume463K

Open$7.38

Beta2.35

Overview

Stock ranking:Biotechnology·Healthcare·View All Market Cap Rankings →

Arcturus Therapeutics Holdings Inc. (ARCT) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · ARCT · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-2.83Earnings history

PE Ratio (TTM)—PE Ratio deep dive

Revenue (TTM)$45.4MFull revenue history

Dividend Yield1.29%Dividend history

Shares Outstanding27.4MShares outstanding history

Next EarningsAug 10, 2026Est.Earnings history

Explore Arcturus Therapeutics Holdings Inc. Data

Market Cap$202.4M

Analyst Forecast$23 · Buy

Dividends1.29%

Revenue$67.2M-51.43%

EarningsEPS $-2.40+20.00%

PE Ratio—

Financial Snapshot

Full Financials

FY 2025Revenue$67.2M▼ 51.43% YoY

202320242025

FY 2025Net Income-$65.8M▲ +18.73% YoY

202320242025

FY 2025EPS$-2.40▲ +20.00% YoY

202320242025

TTM:Revenue: $45.4MNet Income: -$78.7MEPS: $-2.83View income statement →

Analyst Ratings & Price Target

Full Forecast

Buy21 analysts

Strong Buy

Buy

Hold

Sell

Strong Sell

12-Month Price Target

$20.00Low

$7.12Current

$22.50Avg Target216.01% upside

$25.00High

Total: 21 · Buy rate: 57.1%

The ARCT analyst consensus is Buy, based on ratings from 21 Wall Street analysts over the past 3 months. The average 12-month price target is $22.50, representing +216.01% upside from the current price of $7.12.

Competitors & Peers

#TickerCompanyPriceChangeMkt Cap

ARCT

Arcturus Therapeutics Holdings Inc.

$7.12-2.47%$202.4M #2

ACHV

Achieve Life Sciences, Inc.

$5.48+6.82%$562.6M #3

AVIR

Atea Pharmaceuticals, Inc.

$4.32+1.65%$345.7M #4

FHTX

Foghorn Therapeutics Inc.

$3.71-0.54%$217.8M #5

HUMA

Humacyte, Inc.

$1.38+2.22%$231.8M #6

IMRX

Immuneering Corporation

$3.93-7.96%$142.7M

Stock Performance

Full History

1D-1.44%

1W-5.08%

1M-21.96%

3M+1.20%

YTD+17.37%

1Y-42.62%

5Y-77.87%

About Arcturus Therapeutics Holdings Inc.

CEOJoseph E. Payne

IPO DateMay 22, 2013

Employees174

CountryUS

Websitearcturusrx.com

Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respira…

Biotechnology HealthcareNASDAQUS

About Stock Overview & Key Data

Arcturus Therapeutics Holdings Inc. (ARCT) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since May 22, 2013. As of the latest trading session, ARCT stock price is $7.12, with a market capitalization of $202.4M. The stock has returned -42.62% over the past 12 months and +17.37% year-to-date.

According to 21 Wall Street analysts, the consensus rating for Arcturus Therapeutics Holdings Inc. stock is Buy, with an average 12-month price target of $22.50. In fiscal year 2025, Arcturus Therapeutics Holdings Inc. reported revenue of $67.2M and net income of -$65.8M. For detailed data — including Arcturus Therapeutics Holdings Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Arcturus Therapeutics Holdings Inc. (ARCT) stock price is $7.12. The stock is traded on NASDAQ under the ticker symbol ARCT. The 52-week range is $5.85 – $24.17.

ARCT stock priceARCT quote todaylive ticker

Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice